24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
NAB-PACLIEVA 100 MG is an Injection medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | NAB-PACLIEVA 100 MG |
|---|---|
| Composition | Paclitaxel (Protein Bound Particles) for Injection Suspension 100 MG |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Injection |
| Packaging | Vial |
| Country of Origin | India |
NAB-PACLIEVA 100 MG (Paclitaxel (Protein Bound Particles) for Injection Suspension 100 MG) is a widely used Injection medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
NAB-PACLIEVA 100 MG (Paclitaxel Protein-Bound Particles for Injection Suspension 100 mg) is a prescription anticancer medicine containing Paclitaxel 100 mg formulated as albumin-bound (protein-bound) nanoparticles for intravenous administration. This advanced formulation is designed to improve the delivery of Paclitaxel to tumor tissues while eliminating the need for certain solvent-based excipients used in conventional paclitaxel formulations.
Paclitaxel belongs to a class of medicines known as Taxane Antineoplastic Agents, which work by interfering with the normal function of microtubules inside cancer cells. By stabilizing microtubules and preventing their breakdown, Paclitaxel inhibits cell division and ultimately leads to cancer cell death.
NAB-PACLIEVA 100 MG is widely used in the treatment of several cancers, including breast cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer. It may be administered alone or in combination with other anticancer medicines depending on the treatment protocol and patient condition.
The albumin-bound technology enhances drug transport and allows effective chemotherapy delivery without the need for certain solvent-related premedications commonly required with conventional Paclitaxel formulations.
NAB-PACLIEVA 100 MG is commonly prescribed for:
Manufactured according to stringent pharmaceutical quality standards, NAB-PACLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving treatment require regular monitoring of blood counts, liver function, and overall health status throughout therapy.
Due to its proven efficacy and innovative formulation, NAB-PACLIEVA 100 MG remains an important option in modern oncology treatment.
NAB-PACLIEVA 100 MG (Paclitaxel Protein-Bound Particles for Injection Suspension 100 mg) is primarily used in the treatment and management of various cancers.
The medicine is widely used in patients with advanced or metastatic breast cancer.
NAB-Paclitaxel is commonly administered in combination chemotherapy regimens for NSCLC.
The medicine is frequently used in combination with Gemcitabine for advanced pancreatic cancer treatment.
Doctors may prescribe the medicine as part of comprehensive oncology treatment programs.
NAB-PACLIEVA is commonly used alongside other anticancer medicines.
The medicine is incorporated into internationally recognized cancer treatment guidelines.
Treatment may help slow disease progression and improve therapeutic outcomes.
Paclitaxel belongs to a class of medicines known as Taxane Anticancer Agents.
NAB-PACLIEVA works by:
This mechanism helps control cancer growth and supports effective disease management.
Like all medicines, NAB-PACLIEVA 100 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Reduction in white blood cells, red blood cells, and platelets may occur.
Weakness and tiredness are commonly reported.
Temporary hair loss may occur during treatment.
Numbness, tingling, or pain in the hands and feet may develop.
Digestive discomfort may occur during treatment.
Some patients may experience digestive disturbances.
Musculoskeletal discomfort may occur after treatment.
Reduced appetite may affect nutritional intake.
Low white blood cell counts may increase susceptibility to infections.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of NAB-PACLIEVA 100 MG (Paclitaxel Protein-Bound Particles for Injection Suspension 100 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the cancer being treated.
Dosage is generally calculated according to body surface area.
Laboratory monitoring helps guide treatment decisions.
Hepatic function may influence dosage planning.
Concurrent anticancer medicines may affect treatment schedules.
Before starting treatment, inform your doctor if you have:
Patients receiving NAB-Paclitaxel therapy may require:
Patients should also disclose all prescription medicines, supplements, vitamins, and herbal products they are taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is primarily used for metastatic breast cancer, non-small cell lung cancer, and pancreatic cancer treatment.
NAB-Paclitaxel is an albumin-bound formulation of Paclitaxel designed to improve drug delivery to cancer tissues.
Yes. It is a taxane-based chemotherapy medicine.
The albumin-bound formulation eliminates the need for certain solvent-based carriers and may improve drug delivery.
Yes. Temporary hair loss is a common side effect during treatment.
Yes. Peripheral neuropathy, including numbness and tingling in the hands and feet, may occur.
Yes. The medicine may reduce white blood cells, red blood cells, and platelet counts.
Yes. This medicine should only be administered by qualified healthcare professionals experienced in oncology treatment.